inflammasome inflammasomes IL-1beta IL-18 Inflammatory disease pyroptosis IMMvention Therapeutix is a biotechnology company focused on improving the lives of patients with rare and prevalent auto-inflammatory diseases that collectively affect >25 million people in the US. We are discovering and developing novel disease modifying therapies that inhibit the inflammation caused by activation of inflammasomes. The Company’s differentiation is in its novel product pipeline powered by the intellectual capital of its team and a platform to discover small molecule inhibitors of **multiple** inflammasome receptors. The current 1st generation *single* receptor inflammasome inhibition approaches of other companies (such as IFM/Novartis, Nodthera, Inflazome etc.) are expected to be ineffective/suboptimal against diseases where **multiple** receptors are activated. The Company’s initial target diseases are rare auto-inflammatory diseases (e.g. Bullous Pemphigoid, a blistering disease). The Company was co-founded in 2017 by pioneering scientists in the fields of immunology and innate immunity from the School of Medicine and Eshelman School of Pharmacy at the University of North Carolina-Chapel Hill. This includes, Dr. Jenny Ting who is preeminent scientific leader in fields of immunology, innate immunity and inflammasomes. The company is just coming out of stealth mode to raise its first venture funding to progress its novel small molecule preclinical therapeutics pipeline to the clinic for treating rare auto-inflammatory diseases.